Blue Trust Inc. Has $357,000 Position in Cencora, Inc. $COR

Blue Trust Inc. lifted its stake in Cencora, Inc. (NYSE:COR) by 8.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,190 shares of the company’s stock after acquiring an additional 96 shares during the quarter. Blue Trust Inc.’s holdings in Cencora were worth $357,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Voleon Capital Management LP acquired a new position in shares of Cencora during the 1st quarter worth approximately $3,111,000. Exchange Traded Concepts LLC increased its position in shares of Cencora by 4.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company’s stock worth $307,000 after purchasing an additional 48 shares during the last quarter. Focus Partners Wealth increased its holdings in Cencora by 25.8% during the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after buying an additional 1,171 shares during the last quarter. Fiduciary Alliance LLC acquired a new position in Cencora during the second quarter worth $262,000. Finally, Martin Capital Partners LLC increased its holdings in Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after buying an additional 2,544 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Evercore ISI set a $340.00 price objective on shares of Cencora in a research note on Wednesday, October 8th. Jefferies Financial Group boosted their price target on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Weiss Ratings reissued a “buy (b)” rating on shares of Cencora in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a report on Saturday. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $320.00.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the sale, the chief executive officer owned 39,274 shares of the company’s stock, valued at approximately $11,389,460. The trade was a 11.49% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,993 shares of company stock worth $16,292,923. 10.80% of the stock is owned by company insiders.

Cencora Stock Performance

Shares of NYSE COR opened at $317.24 on Tuesday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The stock’s fifty day moving average price is $297.46 and its two-hundred day moving average price is $292.16. Cencora, Inc. has a one year low of $221.95 and a one year high of $319.87. The firm has a market cap of $61.51 billion, a price-to-earnings ratio of 32.64, a P/E/G ratio of 1.49 and a beta of 0.63.

Cencora (NYSE:COR) last released its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.21. The company had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.Cencora’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm posted $3.34 EPS. On average, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were given a $0.55 dividend. The ex-dividend date was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is 22.63%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.